Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

British Journal of Haematology

Volumn 162, Issue 1, 2013, Pages 62-73

  Hillmen, Peter ^a   Muus, Petra ^b   Röth, Alexander ^c   Elebute, Modupe O ^d   Risitano, Antonio M ^e   Schrezenmeier, Hubert ^f   Szer, Jeffrey ^g   Browne, Paul ^h   Maciejewski, Jaroslaw P ⁱ   Schubert, Jörg ^j   Urbano Ispizua, Alvaro ^k   de Castro, Carlos ^l   Socié, Gérard ^m   Brodsky, Robert A ⁿ  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF ULM   (Germany)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h ST JAMES S HOSPITAL   (Ireland)

ⁱ TAUSSIG CANCER INSTITUTE   (United States)

^j SAARLAND UNIVERSITY   (Germany)

^k Grupo de Trabajo de HPN de la Sociedad Española de Hematología y Hemoterapia   (Spain)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Eculizumab; Haemolysis; Long term therapy; Paroxysmal nocturnal haemoglobinuria; Phase III

Indexed keywords

ECULIZUMAB; HEMOGLOBIN; LACTATE DEHYDROGENASE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; CELLULITIS; CHRONIC KIDNEY DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEMATOMA; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HERPETIC STOMATITIS; HUMAN; INSOMNIA; LETHARGY; LIMB PAIN; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; MORTALITY; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; OROPHARYNX PAIN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SEPSIS; SEPTIC SHOCK; SINUSITIS; SURVIVAL TIME; THROMBOSIS; TOOTH PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; VIRUS INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD TRANSFUSION; FEMALE; HEMOGLOBINS; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879121370     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12347     Document Type: Article

References (34)

1. van Bijnen, S.T., van Rijn, R.S., Koljenovic, S., Te Boekhorst, P. & Muus, P. (2012) Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab. British Journal of Haematology, 157, 762-763.
2. Brodsky, R.A. (2009) How I treat paroxysmal nocturnal hemoglobinuria. Blood, 113, 6522-6527.
3. Brodsky, R.A., Young, N.S., Antonioli, E., Risitano, A.M., Schrezenmeier, H., Schubert, J., Gaya, A., Coyle, L., de Castro, C., Fu, C.L., Maciejewski, J.P., Bessler, M., Kroon, H.A., Rother, R.P. & Hillmen, P. (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood, 111, 1840-1847.
4. Clark, D.A., Butler, S.A., Braren, V., Hartmann, R.C. & Jenkins, Jr, D.E. (1981) The kidneys in paroxysmal nocturnal hemoglobinuria. Blood, 57, 83-89.
5. Emadi, A. & Brodsky, R.A. (2009) Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 84, 699-701.
6. Figueroa, J.E. & Densen, P. (1991) Infectious diseases associated with complement deficiencies. Clinical Microbiology Reviews, 4, 359-395.
7. Hill, A., Rother, R.P. & Hillmen, P. (2005a) Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal haemoglobinuria. 'Haematologica' 90, 40.
8. Hill, A., Hillmen, P., Richards, S.J., Elebute, D., Marsh, J.C., Chan, J., Mojcik, C.F. & Rother, R.P. (2005b) Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood, 106, 2559-2565.
9. Hill, A., Rother, R.P., Wang, X., Morris, Jr, S.M., Quinn-Senger, K., Kelly, R., Richards, S.J., Bessler, M., Bell, L., Hillmen, P. & Gladwin, M.T. (2010) Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 149, 414-425.
10. Hill, A., Sapsford, R.J., Scally, A., Kelly, R., Richards, S.J., Khurisgara, G., Sivananthan, M.U. & Hillmen, P. (2012) Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. British Journal of Haematology, 158, 409-414.
11. Hillmen, P., Lewis, S.M., Bessler, M., Luzzatto, L. & Dacie, J.V. (1995) Natural history of paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 333, 1253-1258.
12. Hillmen, P., Hall, C., Marsh, J.C., Elebute, M., Bombara, M.P., Petro, B.E., Cullen, M.J., Richards, S.J., Rollins, S.A., Mojcik, C.F. & Rother, R.P. (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 350, 552-559.
13. Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socié, G., Muus, P., Roth, A., Szer, J., Elebute, M.O., Nakamura, R., Browne, P., Risitano, A.M., Hill, A., Schrezenmeier, H., Fu, C.L., Maciejewski, J., Rollins, S.A., Mojcik, C.F., Rother, R.P. & Luzzatto, L. (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 355, 1233-1243.
14. Hillmen, P., Muus, P., Dührsen, U., Risitano, A.M., Schubert, J., Luzzatto, L., Schrezenmeier, H., Szer, J., Brodsky, R.A., Hill, A., Socié, G., Bessler, M., Rollins, S.A., Bell, L., Rother, R.P. & Young, N.S. (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood, 110, 4123-4128.
15. Hillmen, P., Elebute, M., Kelly, R., Urbano-Ispizua, A., Hill, A., Rother, R.P., Khursigara, G., Fu, C.L., Omine, M., Browne, P. & Rosse, W. (2010) Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 85, 553-559.
16. Kelly, R., Richards, S., Hillmen, P. & Hill, A. (2009) The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Therapeutics and Clinical Risk Managment, 5, 911-921.
17. Kelly, R., Arnold, L., Richards, S., Hill, A., Bomken, C., Hanley, J., Loughney, A., Beauchamp, J., Khursigara, G., Rother, R.P., Chalmers, E., Fyfe, A., Fitzsimons, E., Nakamura, R., Gaya, A., Risitano, A.M., Schubert, J., Norfolk, D., Simpson, N. & Hillmen, P. (2010) The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. British Journal of Haematology, 149, 446-450.
18. Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Mitchell, L.D., Cohen, D.R., Gregory, W.M. & Hillmen, P. (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood, 117, 6786-6792.
19. Kim, J.S., Jang, J.H., Lee, J.W., Yoon, S.S., Lee, J.H., Kim, Y.K., Sohn, S.K. & Chung, J.S. (2011) Renal impairment ia a risk factor for early mortality in patients with paroxysmal nocturnal haemoglobinuria (PNH). Haematologica, 96, 112.
20. de Latour, R.P., Mary, J.Y., Salanoubat, C., Terriou, L., Etienne, G., Mohty, M., Roth, S., de Guibert S., Maury, S., Cahn, J.Y. & Socié, G. (2008) Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood, 112, 3099-3106.
21. de Latour, R.P., Schrezenmeier, H., Mary, J.-Y., Bacigalupo, A., de Souza, C., Willemze, R., Tichelli, A., Passweg, J.R. & Socié, G. (2009) Stem cell transplantation for paroxysmal nocturnal haemoglobinuria: an on going joint study of the AAWP EBMT Group and the French Society of Haematology. (Abstract). Bone Marrow Transplantation, 43, S57-S58.
22. Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N. & Roth, D. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine, 130, 461-470.
23. McKeage, K. (2011) Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs, 71, 2327-2345.
24. Moyo, V.M., Mukhina, G.L., Garrett, E.S. & Brodsky, R.A. (2004) Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. British Journal of Haematology, 126, 133-138.
25. Nath, K.A., Vercellotti, G.M., Grande, J.P., Miyoshi, H., Paya, C.V., Manivel, J.C., Haggard, J.J., Croatt, A.J., Payne, W.D. & Alam, J. (2001) Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney International, 59, 106-117.
26. National Kidney Foundation. (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases, 39, S1-266.
27. Nishimura, J., Kanakura, Y., Ware, R.E., Shichishima, T., Nakakuma, H., Ninomiya, H., Decastro, C.M., Hall, S., Kanamaru, A., Sullivan, K.M., Mizoguchi, H., Omine, M., Kinoshita, T. & Rosse, W.F. (2004) Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine, 83, 193-207.
28. Parker, C.J. (1991) Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement. Clinical and Experimental Immunology, 86(Suppl. 1), 36-42.
29. Pu, J.J. & Brodsky, R.A. (2011) Paroxysmal nocturnal hemoglobinuria from bench to bedside. Clinical and Translational Science, 4, 219-224.
30. Rother, R.P., Bell, L., Hillmen, P. & Gladwin, M.T. (2005) The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA, 293, 1653-1662.
31. Rother, R.P., Rollins, S.A., Mojcik, C.F., Brodsky, R.A. & Bell, L. (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnology, 25, 1256-1264.
32. Socié, G., Mary, J.Y., de Gramont, A., Rio, B., Leporrier, M., Rose, C., Heudier, P., Rochant, H., Cahn, J.Y. & Gluckman, E. (1996) Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French society of Haematology. Lancet, 348, 573-577.
33. Stevens, L.A., Coresh, J., Greene, T. & Levey, A.S. (2006) Assessing kidney function-measured and estimated glomerular filtration rate. New England Journal of Medicine, 354, 2473-2483.
34. Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T. & Kinoshita, T. (1993) Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell, 73, 703-711.